{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T04:20:22Z","timestamp":1787804422784,"version":"build-2784847793"},"reference-count":80,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.jconrel.2026.115126","type":"journal-article","created":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T16:19:49Z","timestamp":1782317989000},"page":"115126","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Local delivery of SN-38 for the treatment of glioblastoma: Engineering precision chemotherapy beyond the blood\u2013brain barrier"],"prefix":"10.1016","volume":"397","author":[{"given":"Ann-Kathrin","family":"Gruber","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ester","family":"Lopera de Llanos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Huguet Ninou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucas","family":"Krauel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"P\u00e9rez-Campos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Antonio","family":"Tornero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.jconrel.2026.115126_bb0005","first-page":"299","article-title":"Management of glioblastoma: state of the art and future directions","volume":"70","author":"Tan","year":"2020","journal-title":"CA Cancer J. Clin."},{"issue":"17","key":"10.1016\/j.jconrel.2026.115126_bb0010","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15174279","article-title":"Recurrent glioblastoma: a review of the treatment options","volume":"15","author":"Vaz-Salgado","year":"2023","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.jconrel.2026.115126_bb0015","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s11060-009-0103-2","article-title":"Phase II NCCTG trial of RT + irinotecan and adjuvant BCNU plus irinotecan for newly diagnosed GBM","volume":"99","author":"Jaeckle","year":"2010","journal-title":"J. Neuro-Oncol."},{"issue":"28","key":"10.1016\/j.jconrel.2026.115126_bb0020","doi-asserted-by":"crossref","first-page":"4733","DOI":"10.1200\/JCO.2008.19.8721","article-title":"Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma","volume":"27","author":"Friedman","year":"2009","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.jconrel.2026.115126_bb0025","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1215\/15228517-2008-075","article-title":"Experience with irinotecan for the treatment of malignant glioma","volume":"11","author":"Vredenburgh","year":"2009","journal-title":"Neuro-Oncol."},{"issue":"11","key":"10.1016\/j.jconrel.2026.115126_bb0030","doi-asserted-by":"crossref","first-page":"3728","DOI":"10.1158\/1078-0432.CCR-03-0807","article-title":"Plasma and cerebrospinal fluid population pharmacokinetics of Temozolomide in malignant glioma patients","volume":"10","author":"Ostermann","year":"2004","journal-title":"Clin. Cancer Res."},{"issue":"10","key":"10.1016\/j.jconrel.2026.115126_bb0035","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1056\/NEJMoa043331","article-title":"MGMT gene silencing and benefit from Temozolomide in glioblastoma","volume":"352","author":"Hegi","year":"2005","journal-title":"N. Engl. J. Med."},{"issue":"11","key":"10.1016\/j.jconrel.2026.115126_bb0040","doi-asserted-by":"crossref","first-page":"5557","DOI":"10.3390\/ijms22115557","article-title":"Enhanced anti-tumor activity in mice with Temozolomide-resistant human glioblastoma cell line-derived xenograft using SN-38-incorporated polymeric microparticle","volume":"22","author":"Yang","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"12","key":"10.1016\/j.jconrel.2026.115126_bb0045","doi-asserted-by":"crossref","first-page":"1911","DOI":"10.1517\/17425247.2015.1070142","article-title":"Challenges in SN38 drug delivery: current success and future directions","volume":"12","author":"Palakurthi","year":"2015","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.jconrel.2026.115126_bb0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2023.122886","article-title":"Recent advances in SN-38 drug delivery system","volume":"637","author":"Yang","year":"2023","journal-title":"Int. J. Pharm."},{"issue":"12","key":"10.1016\/j.jconrel.2026.115126_bb0055","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1177\/1535370215590819","article-title":"Antitumor efficacy and intratumoral distribution of SN-38 from polymeric depots in brain tumor model","volume":"240","author":"Vejjasilpa","year":"2015","journal-title":"Exp. Biol. Med. Maywood NJ"},{"issue":"6","key":"10.1016\/j.jconrel.2026.115126_bb0060","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.3171\/2022.9.JNS22715","article-title":"Intranasal delivery of nanoliposomal SN-38 for treatment of diffuse midline glioma","volume":"138","author":"Sasaki","year":"2023","journal-title":"J. Neurosurg."},{"issue":"1","key":"10.1016\/j.jconrel.2026.115126_bb0065","doi-asserted-by":"crossref","first-page":"14175","DOI":"10.1038\/s41598-024-64186-2","article-title":"PLX038A, a long-acting SN-38, penetrates the blood-tumor-brain-barrier, accumulates and releases SN-38 in brain tumors to increase survival of tumor bearing mice","volume":"14","author":"Jung","year":"2024","journal-title":"Sci. Rep."},{"issue":"14","key":"10.1016\/j.jconrel.2026.115126_bb0070","article-title":"Targeted delivery of DNA topoisomerase inhibitor SN38 to intracranial tumors of glioblastoma using Sub-5 ultrafine Iron oxide nanoparticles","volume":"11","author":"Li","year":"2022","journal-title":"Adv. Healthc. Mater."},{"issue":"7","key":"10.1016\/j.jconrel.2026.115126_bb0075","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1007\/s10856-021-06538-2","article-title":"SN38 loaded nanostructured lipid carriers (NLCs); preparation and in vitro evaluations against glioblastoma","volume":"32","author":"Shirazi","year":"2021","journal-title":"J. Mater. Sci. Mater. Med."},{"issue":"2","key":"10.1016\/j.jconrel.2026.115126_bb0080","doi-asserted-by":"crossref","first-page":"2615","DOI":"10.1021\/acsomega.3c07486","article-title":"Development of a targeted SN-38-conjugate for the treatment of glioblastoma","volume":"9","author":"Bataille Backer","year":"2024","journal-title":"ACS Omega"},{"issue":"2","key":"10.1016\/j.jconrel.2026.115126_bb0085","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1093\/neuonc\/nox175","article-title":"Is the blood-brain barrier really disrupted in all glioblastomas? A critical assessment of existing clinical data","volume":"20","author":"Sarkaria","year":"2018","journal-title":"Neuro-Oncol."},{"key":"10.1016\/j.jconrel.2026.115126_bb0090","first-page":"1","article-title":"Overcoming the blood-brain tumor barrier for effective glioblastoma treatment","volume":"19","author":"van Tellingen","year":"2015","journal-title":"Drug Resist. Updat Rev. Comment Antimicrob. Anticancer Chemother."},{"issue":"4","key":"10.1016\/j.jconrel.2026.115126_bb0095","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1038\/s41582-022-00621-0","article-title":"Advances in local therapy for glioblastoma - taking the fight to the tumour","volume":"18","author":"van Solinge","year":"2022","journal-title":"Nat. Rev. Neurol."},{"issue":"1","key":"10.1016\/j.jconrel.2026.115126_bb0100","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s11060-012-0983-4","article-title":"Failure pattern following complete resection plus radiotherapy and temozolomide is at the resection margin in patients with glioblastoma","volume":"111","author":"Petrecca","year":"2013","journal-title":"J. Neuro-Oncol."},{"issue":"10","key":"10.1016\/j.jconrel.2026.115126_bb0105","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1038\/nrc1977","article-title":"Topoisomerase I inhibitors: camptothecins and beyond","volume":"6","author":"Pommier","year":"2006","journal-title":"Nat. Rev. Cancer"},{"issue":"7","key":"10.1016\/j.jconrel.2026.115126_bb0110","doi-asserted-by":"crossref","first-page":"6231","DOI":"10.1021\/acsabm.5c00722","article-title":"Safe and efficient intracellular release of SN38 via lysosomal-responsive SN38-G loaded liposomes","volume":"8","author":"Burnouf","year":"2025","journal-title":"ACS Appl. Bio Mater."},{"key":"10.1016\/j.jconrel.2026.115126_bb0115","doi-asserted-by":"crossref","first-page":"945","DOI":"10.2147\/IJN.S435407","article-title":"Research Progress of SN38 drug delivery system in Cancer treatment","volume":"19","author":"Qi","year":"2024","journal-title":"Int. J. Nanomedicine"},{"issue":"5","key":"10.1016\/j.jconrel.2026.115126_bb0120","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S0166-2236(98)01261-2","article-title":"Extracellular space structure revealed by diffusion analysis","volume":"21","author":"Nicholson","year":"1998","journal-title":"Trends Neurosci."},{"issue":"suppl_2","key":"10.1016\/j.jconrel.2026.115126_bb0125","doi-asserted-by":"crossref","first-page":"ii9","DOI":"10.1093\/neuonc\/nou360","article-title":"Polymeric drug delivery for the treatment of glioblastoma","volume":"17","author":"Wait","year":"2015","journal-title":"Neuro-Oncol."},{"key":"10.1016\/j.jconrel.2026.115126_bb0130","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.jmbbm.2015.02.024","article-title":"Mechanical properties of gray and white matter brain tissue by indentation","volume":"46","author":"Budday","year":"2015","journal-title":"J. Mech. Behav. Biomed. Mater."},{"issue":"8956","key":"10.1016\/j.jconrel.2026.115126_bb0135","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1016\/S0140-6736(95)90755-6","article-title":"Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas","volume":"345","author":"Brem","year":"1995","journal-title":"Lancet"},{"key":"10.1016\/j.jconrel.2026.115126_bb0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2026.105144","article-title":"Innovative approaches to irinotecan-based therapies for glioblastoma: advancements in drug delivery and combination strategies","volume":"219","author":"Hsu","year":"2026","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"1","key":"10.1016\/j.jconrel.2026.115126_bb0145","article-title":"Why do glioblastoma treatments fail?","volume":"5","author":"Ron\u010devi\u0107","year":"2025","journal-title":"Fut. Pharmacol."},{"issue":"5","key":"10.1016\/j.jconrel.2026.115126_bb0150","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/S1470-2045(06)70665-9","article-title":"Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial","volume":"7","author":"Stummer","year":"2006","journal-title":"Lancet Oncol."},{"issue":"4","key":"10.1016\/j.jconrel.2026.115126_bb0155","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1007\/s10143-014-0546-6","article-title":"Fluorescein-guided surgery for malignant gliomas: a review","volume":"37","author":"Acerbi","year":"2014","journal-title":"Neurosurg. Rev."},{"issue":"2","key":"10.1016\/j.jconrel.2026.115126_bb0160","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14020443","article-title":"Tumor cell infiltration into the brain in glioblastoma: from mechanisms to clinical perspectives","volume":"14","author":"Seker-Polat","year":"2022","journal-title":"Cancers"},{"issue":"18","key":"10.1016\/j.jconrel.2026.115126_bb0165","doi-asserted-by":"crossref","DOI":"10.3390\/ijms221810005","article-title":"Novel concepts of glioblastoma therapy concerning its heterogeneity","volume":"22","author":"Hut\u00f3czki","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.jconrel.2026.115126_bb0170","doi-asserted-by":"crossref","DOI":"10.3389\/fphy.2025.1723329","article-title":"Molecular and biophysical remodeling of the blood\u2013brain barrier in glioblastoma: mechanistic drivers of tumor\u2013neurovascular crosstalk","volume":"13","author":"Abikenari","year":"2025","journal-title":"Front. Phys."},{"issue":"5","key":"10.1016\/j.jconrel.2026.115126_bb0175","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.neurol.2023.03.013","article-title":"Overcoming the blood brain barrier in glioblastoma: status and future perspective","volume":"179","author":"Ahmed","year":"2023","journal-title":"Rev. Neurol. (Paris)"},{"issue":"1","key":"10.1016\/j.jconrel.2026.115126_bb0180","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.nbd.2009.07.030","article-title":"Structure and function of the blood\u2013brain barrier","volume":"37","author":"Abbott","year":"2010","journal-title":"Neurobiol. Dis."},{"issue":"3","key":"10.1016\/j.jconrel.2026.115126_bb0185","first-page":"287","article-title":"Drug resistance in glioblastoma: are persisters the key to therapy?","volume":"3","author":"Oliver","year":"2020","journal-title":"Cancer Drug Resist."},{"issue":"5","key":"10.1016\/j.jconrel.2026.115126_bb0190","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.mam.2012.02.003","article-title":"The disturbed blood\u2013brain barrier in human glioblastoma","volume":"33","author":"Wolburg","year":"2012","journal-title":"Mol. Asp. Med."},{"issue":"3","key":"10.1016\/j.jconrel.2026.115126_bb0195","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1007\/s10555-020-09877-8","article-title":"Brain tumor vessels-a barrier for drug delivery","volume":"39","author":"Hempel","year":"2020","journal-title":"Cancer Metastasis Rev."},{"issue":"6","key":"10.1016\/j.jconrel.2026.115126_bb0200","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.3390\/biomedicines11061579","article-title":"Personalized treatment of glioblastoma: current state and future perspective","volume":"11","author":"Ron\u010devi\u0107","year":"2023","journal-title":"Biomedicines"},{"issue":"4","key":"10.1016\/j.jconrel.2026.115126_bb0205","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1039\/D1BM01401C","article-title":"Radiotherapy for glioblastoma: clinical issues and nanotechnology strategies","volume":"10","author":"Li","year":"2022","journal-title":"Biomater. Sci."},{"issue":"1","key":"10.1016\/j.jconrel.2026.115126_bb0210","first-page":"17","article-title":"Mechanisms of temozolomide resistance in glioblastoma - a comprehensive review","volume":"4","author":"Singh","year":"2021","journal-title":"Cancer Drug Resist. Alhambra Calif."},{"issue":"9","key":"10.1016\/j.jconrel.2026.115126_bb0215","first-page":"1181","article-title":"Blood-brain barrier-associated efflux transporters: a significant but underappreciated obstacle to drug development in glioblastoma","volume":"17","author":"Mason","year":"2015","journal-title":"Neuro-Oncol."},{"issue":"2","key":"10.1016\/j.jconrel.2026.115126_bb0220","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s11060-004-6152-7","article-title":"Expression of drug resistance proteins Pgp, MRP1, MRP3, MRP5 AND GST-\u03c0 in human glioma","volume":"74","author":"Calatozzolo","year":"2005","journal-title":"J. Neuro-Oncol."},{"issue":"6","key":"10.1016\/j.jconrel.2026.115126_bb0225","doi-asserted-by":"crossref","first-page":"403","DOI":"10.2165\/00003088-200241060-00002","article-title":"Pharmacokinetics of the carmustine implant","volume":"41","author":"Fleming","year":"2002","journal-title":"Clin. Pharmacokinet."},{"issue":"2","key":"10.1016\/j.jconrel.2026.115126_bb0230","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1093\/neuonc\/5.2.79","article-title":"A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma","volume":"5","author":"Westphal","year":"2003","journal-title":"Neuro-Oncol."},{"issue":"1","key":"10.1016\/j.jconrel.2026.115126_bb0235","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1186\/s12957-016-0975-5","article-title":"Gliadel wafer implantation combined with standard radiotherapy and concurrent followed by adjuvant temozolomide for treatment of newly diagnosed high-grade glioma: a systematic literature review","volume":"14","author":"Ashby","year":"2016","journal-title":"World J. Surg. Oncol."},{"issue":"2","key":"10.1016\/j.jconrel.2026.115126_bb0240","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/s11060-015-1724-2","article-title":"Survival outcomes and safety of carmustine wafers in the treatment of high-grade gliomas: a meta-analysis","volume":"122","author":"Chowdhary","year":"2015","journal-title":"J. Neuro-Oncol."},{"issue":"1","key":"10.1016\/j.jconrel.2026.115126_bb0245","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0168-3659(01)00311-X","article-title":"Biodegradable polymer implants to treat brain tumors","volume":"74","author":"Brem","year":"2001","journal-title":"J. Control. Release"},{"issue":"1","key":"10.1016\/j.jconrel.2026.115126_bb0250","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1215\/S1152851704000614","article-title":"Cerebral edema associated with Gliadel wafers: two case studies","volume":"7","author":"Weber","year":"2005","journal-title":"Neuro-Oncol."},{"issue":"15","key":"10.1016\/j.jconrel.2026.115126_bb0255","doi-asserted-by":"crossref","first-page":"3743","DOI":"10.3390\/cancers14153743","article-title":"Molecular pathways and genomic landscape of glioblastoma stem cells: opportunities for targeted therapy","volume":"14","author":"Hersh","year":"2022","journal-title":"Cancers"},{"issue":"12","key":"10.1016\/j.jconrel.2026.115126_bb0260","doi-asserted-by":"crossref","first-page":"3373","DOI":"10.1002\/pola.1987.080251217","article-title":"Preparation of high molecular weight polyanhydrides","volume":"25","author":"Domb","year":"1987","journal-title":"J. Polym. Sci. Part Polym Chem."},{"issue":"6","key":"10.1016\/j.jconrel.2026.115126_bb0265","doi-asserted-by":"crossref","first-page":"907","DOI":"10.3390\/cancers18060907","article-title":"Limitations of Gliadel wafers and strategies for next-generation local delivery Systems for Glioblastoma","volume":"18","author":"Kartal","year":"2026","journal-title":"Cancers"},{"issue":"17","key":"10.1016\/j.jconrel.2026.115126_bb0270","doi-asserted-by":"crossref","first-page":"3008","DOI":"10.3390\/cancers16173008","article-title":"Local delivery of irinotecan to recurrent GBM patients at reoperation offers a safe route of administration","volume":"16","author":"McConville","year":"2024","journal-title":"Cancers"},{"key":"10.1016\/j.jconrel.2026.115126_bb0275","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jconrel.2020.05.012","article-title":"Development and in vivo evaluation of irinotecan-loaded drug eluting seeds (iDES) for the localised treatment of recurrent glioblastoma multiforme","volume":"324","author":"Gawley","year":"2020","journal-title":"J. Control Release Off. J. Control Release Soc."},{"issue":"11","key":"10.1016\/j.jconrel.2026.115126_bb0280","doi-asserted-by":"crossref","first-page":"3070","DOI":"10.1007\/s13346-024-01524-x","article-title":"Local administration of irinotecan using an implantable drug delivery device stops high-grade glioma tumor recurrence in a glioblastoma tumor model","volume":"14","author":"Abdelnabi","year":"2024","journal-title":"Drug Deliv. Transl. Res."},{"key":"10.1016\/j.jconrel.2026.115126_bb0285","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.colsurfb.2015.06.055","article-title":"Concurrent delivery of carmustine, irinotecan, and cisplatin to the cerebral cavity using biodegradable nanofibers: in vitro and in vivo studies","volume":"134","author":"Tseng","year":"2015","journal-title":"Colloids Surf. B: Biointerfaces"},{"issue":"12","key":"10.1016\/j.jconrel.2026.115126_bb0290","doi-asserted-by":"crossref","first-page":"4345","DOI":"10.1002\/jps.24684","article-title":"Anti-neoplastic cytotoxicity of SN-38-loaded PCL\/gelatin electrospun composite nanofiber scaffolds against human glioblastoma cells in vitro","volume":"104","author":"Zhu","year":"2015","journal-title":"J. Pharm. Sci."},{"issue":"1","key":"10.1016\/j.jconrel.2026.115126_bb0295","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1021\/bm401558c","article-title":"Nanofibers support oligodendrocyte precursor cell growth and function as a neuron-free model for myelination study","volume":"15","author":"Li","year":"2014","journal-title":"Biomacromolecules"},{"issue":"14","key":"10.1016\/j.jconrel.2026.115126_bb0300","doi-asserted-by":"crossref","first-page":"3510","DOI":"10.3390\/ma17143510","article-title":"Novel collagen membrane formulations with irinotecan or minocycline for potential application in brain Cancer","volume":"17","author":"Idu","year":"2024","journal-title":"Materials"},{"issue":"10","key":"10.1016\/j.jconrel.2026.115126_bb0305","doi-asserted-by":"crossref","first-page":"3708","DOI":"10.1002\/jps.23238","article-title":"Preparation and in vitro characterization of SN-38-loaded, self-forming polymeric depots as an injectable drug delivery system","volume":"101","author":"Manaspon","year":"2012","journal-title":"J. Pharm. Sci."},{"issue":"12","key":"10.1016\/j.jconrel.2026.115126_bb0310","doi-asserted-by":"crossref","first-page":"2891","DOI":"10.1007\/s11095-016-2011-4","article-title":"Injectable SN-38-loaded polymeric depots for Cancer chemotherapy of glioblastoma Multiforme","volume":"33","author":"Manaspon","year":"2016","journal-title":"Pharm. Res."},{"issue":"4","key":"10.1016\/j.jconrel.2026.115126_bb0315","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1007\/s10856-009-3803-4","article-title":"Doxorubicin and irinotecan drug-eluting beads for treatment of glioma: a pilot study in a rat model","volume":"21","author":"Baltes","year":"2010","journal-title":"J. Mater. Sci. Mater. Med."},{"issue":"5","key":"10.1016\/j.jconrel.2026.115126_bb0320","doi-asserted-by":"crossref","first-page":"479","DOI":"10.3390\/pharmaceutics12050479","article-title":"Injectable SN-38-embedded polymeric microparticles promote antitumor efficacy against malignant glioma in an animal model","volume":"12","author":"Tseng","year":"2020","journal-title":"Pharmaceutics"},{"issue":"Suppl. 1","key":"10.1016\/j.jconrel.2026.115126_bb0325","doi-asserted-by":"crossref","first-page":"i12","DOI":"10.1093\/neuonc\/now293.044","article-title":"PP44. Surgical implantation of irinotecan loaded MICRO-beads offers a novel safe approach to treating patients with recurrent glioblastoma(NCT02433392)","volume":"19","author":"Cruickshank","year":"2017","journal-title":"Neuro-Oncol."},{"issue":"Suppl. 1","key":"10.1016\/j.jconrel.2026.115126_bb0330","article-title":"Local delivery of irinotecan to recurrent glioblastoma at reoperation offers a safe therapeutic advantage over systemic delivery","volume":"20","author":"Cruickshank","year":"2018","journal-title":"Neuro-Oncol."},{"issue":"19","key":"10.1016\/j.jconrel.2026.115126_bb0335","doi-asserted-by":"crossref","first-page":"4836","DOI":"10.1016\/j.biomaterials.2012.03.048","article-title":"MRI-monitored long-term therapeutic hydrogel system for brain tumors without surgical resection","volume":"33","author":"Kim","year":"2012","journal-title":"Biomaterials"},{"issue":"1","key":"10.1016\/j.jconrel.2026.115126_bb0340","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1080\/10837450.2017.1391287","article-title":"Liposome-loaded thermo-sensitive hydrogel for stabilization of SN-38 via intratumoral injection: optimization, characterization, and antitumor activity","volume":"23","author":"Bai","year":"2018","journal-title":"Pharm. Dev. Technol."},{"issue":"19","key":"10.1016\/j.jconrel.2026.115126_bb0345","doi-asserted-by":"crossref","first-page":"7111","DOI":"10.3390\/ijms21197111","article-title":"Injectable Thermo-sensitive chitosan hydrogel containing CPT-11-loaded EGFR-targeted graphene oxide and SLP2 shRNA for localized drug\/gene delivery in glioblastoma therapy","volume":"21","author":"Lu","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.jconrel.2026.115126_bb0350","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s11060-024-04904-y","article-title":"A phase I study of convection-enhanced delivery (CED) of liposomal-irinotecan using real-time magnetic resonance imaging in patients with recurrent high-grade glioma","volume":"172","author":"Narsinh","year":"2025","journal-title":"J. Neuro-Oncol."},{"issue":"1","key":"10.1016\/j.jconrel.2026.115126_bb0355","article-title":"Self-assembling polypeptide-drug conjugates as innovative therapeutic candidates for glioblastoma treatment by enhancing intracranial residence time","volume":"7","author":"Gwon","year":"2025","journal-title":"Neuro Oncol. Adv."},{"issue":"8","key":"10.1016\/j.jconrel.2026.115126_bb0360","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.3109\/10717544.2015.1081994","article-title":"Convection-enhanced delivery of SN-38-loaded polymeric micelles (NK012) enables consistent distribution of SN-38 and is effective against rodent intracranial brain tumor models","volume":"23","author":"Zhang","year":"2016","journal-title":"Drug Deliv."},{"issue":"3","key":"10.1016\/j.jconrel.2026.115126_bb0365","doi-asserted-by":"crossref","first-page":"583","DOI":"10.3171\/2008.5.17557","article-title":"Gliadel (BCNU) wafer plus concomitant temozolomide therapy after primary resection of glioblastoma multiforme","volume":"110","author":"McGirt","year":"2009","journal-title":"J. Neurosurg."},{"issue":"2","key":"10.1016\/j.jconrel.2026.115126_bb0370","doi-asserted-by":"crossref","first-page":"301","DOI":"10.3171\/2009.11.JNS091052","article-title":"Poor drug distribution as a possible explanation for the results of the PRECISE trial","volume":"113","author":"Sampson","year":"2010","journal-title":"J. Neurosurg."},{"issue":"4","key":"10.1016\/j.jconrel.2026.115126_bb0375","doi-asserted-by":"crossref","DOI":"10.3390\/cancers17040701","article-title":"Progress in drug delivery systems based on nanoparticles for improved glioblastoma therapy: addressing challenges and investigating opportunities","volume":"17","author":"Rahman","year":"2025","journal-title":"Cancers"},{"key":"10.1016\/j.jconrel.2026.115126_bb0380","first-page":"492","article-title":"Regulatory perspectives of combination products","volume":"10","author":"Tian","year":"2021","journal-title":"Bioact. Mater."},{"key":"10.1016\/j.jconrel.2026.115126_bb0385","doi-asserted-by":"crossref","first-page":"9597","DOI":"10.2147\/IJN.S531451","article-title":"Advances and challenges in nano-delivery systems for glioblastoma treatment: a comprehensive review","volume":"20","author":"Wang","year":"2025","journal-title":"Int. J. Nanomedicine"},{"issue":"1","key":"10.1016\/j.jconrel.2026.115126_bb0390","article-title":"PNOC009: convection-enhanced delivery of liposomal irinotecan in patients with newly diagnosed diffuse intrinsic pontine glioma","volume":"7","author":"Mueller","year":"2025","journal-title":"Neuro Oncol. Adv."},{"issue":"11","key":"10.1016\/j.jconrel.2026.115126_bb0395","doi-asserted-by":"crossref","DOI":"10.3390\/jpm15110512","article-title":"Leveraging synergy: a review of the therapeutic potential of SN-38 and immune checkpoint blockade in breast and prostate cancer treatment","volume":"15","author":"Adekiya","year":"2025","journal-title":"J. Pers. Med."},{"issue":"12","key":"10.1016\/j.jconrel.2026.115126_bb0400","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002772","article-title":"Sensitizing tumors to anti-PD-1 therapy by promoting NK and CD8+ T cells via pharmacological activation of FOXO3","volume":"9","author":"Chung","year":"2021","journal-title":"J. Immunother. Cancer"}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365926005298?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365926005298?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T04:15:46Z","timestamp":1787804146000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365926005298"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":80,"alternative-id":["S0168365926005298"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2026.115126","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Local delivery of SN-38 for the treatment of glioblastoma: Engineering precision chemotherapy beyond the blood\u2013brain barrier","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2026.115126","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"115126"}}